Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement

   Life Technologies and Advanced Cell Diagnostics Sign Global Distribution

- Partnership makes Advanced Cell Diagnostics' award-winning RNAscope®
technology accessible to researchers worldwide

- Expands Life Technologies' footprint in growing tissue analysis market

PR Newswire

CARLSBAD, Calif., Sept. 30, 2013

CARLSBAD, Calif., Sept. 30, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) and Advanced Cell Diagnostics, Inc. (ACD), a leader in the
field of molecular pathology and developer of cell and tissue-based analysis
tools, today announced a global distribution agreement by which Life will
distribute ACD's fluorescent RNAscope® portfolio of probes and kits to the
research market through its worldwide distribution network.

Kits Support Growing RNA Biomarker Market, Cancer and Neurobiology Research

RNA biomarker discovery and validation for the tissue analysis market is
growing rapidly as the transition between research and the clinic continues to
accelerate. RNAscope® is quickly becoming a gold-standard technique to
identify and validate RNA biomarkers in tissue for research, molecular
diagnostics and companion diagnostics. Additionally, as cancer and
neurobiology research continues to grow, there has been an explosion in the
discovery of biomarkers identified from microarray and next-generation
sequencing (NGS) technologies. However, for many of these biomarkers, the
specific cell types in the tissue that express them remain unknown, thereby
limiting the ability to fully understand biological relevance.

"RNAscope complements our existing portfolio and solves long-standing
technical hurdles researchers have encountered when studying heterogeneous
samples," says Siddhartha Kadia, Ph.D., President, Life Sciences at Life
Technologies.  "RNAscope's ability to provide single-molecule RNA detection,
while preserving tissue context makes it easy to pinpoint which biomarker is
expressed in specific cells -- all at the convenience of a conventional
fluorescence microscope."

RNAscope features exceptional levels of sensitivity, specificity, and the
ability to multiplex -- making it a breakthrough technology for localizing and
measuring RNA in situ in unprecedented detail. It addresses many bottlenecks
that arise due to lack of antibodies, and complements both NGS and qPCR
methods by revealing the valuable, morphological context of newly identified
biomarkers in both cells and complex tissues.

"Advanced Cell Diagnostics is delighted that RNAscope products will be
introduced into multiple markets through Life Technologies extensive
distribution networks," said Yuling Luo, Founder, President & CEO, Advanced
Cell Diagnostics. "Life Technologies has a legacy of introducing cutting-edge
technologies to their customers and we are excited to have them represent

About Life Technologies

Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum—scientific exploration,
molecular diagnostics, 21^stcentury forensics, regenerative medicine and
agricultural research. Life Technologies has approximately 10,000 employees
and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

About Advanced Cell Diagnostics, Inc.

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of
molecular pathology, developing cell and tissue-based research tools for all
areas of biomedical research, and diagnostic tests for personalized medicine.
The company's products and services are based on its proprietary RNAscope®
technology, the most sensitive method available for RNA in situ hybridization,
and the first quantitative and fully automated platform enabling multiplex
fluorescent and chromogenic RNA biomarker analysis. ACD partners with
pharmaceutical and biotechnology companies to validate biomarkers for targeted
therapeutic development in cancer and other diseases. These partnerships
provide the foundation for ACD to develop companion diagnostic tests in
conjunction with partners' targeted therapeutics. ACD also pursues internal
programs to develop proprietary diagnostic tests in cancer management. Learn
more about ACD and RNAscope® technology at


Media Contacts:
Mauricio Minotta
Life Technologies Corp.

Steve Chen
Chief Operating Officer
Advanced Cell Diagnostics Inc.

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.